Milo Gatti

Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients

Milo Gatti, Pier Giorgio Cojutti, Michele Bartoletti et al. · Critical Care · 2022 · 95 citations · Full text

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections

Milo Gatti, Pier Giorgio Cojutti, Renato Pascale et al. · Antibiotics · 2021 · 79 citations · Full text

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

Milo Gatti, Michele Bartoletti, Pier Giorgio Cojutti et al. · Journal of Global Antimicrobial Resistance · 2021 · 73 citations · Full text

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant <i>Pseudomonas aeruginosa</i> (DTR-P) infections

Marianna Meschiari, Sara Volpi, Matteo Faltoni et al. · JAC-Antimicrobial Resistance · 2021 · 65 citations · Full text

Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system

Milo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger et al. · European Journal of Preventive Cardiology · 2020 · 60 citations · Full text